Archive: September 2016

Emerging Treatment Options for Carcinoid Syndrome

Matthew H. Kulke, MD

  H&O  What are carcinoid tumors, and which types are most likely to lead to carcinoid syndrome? MK  Carcinoid tumors fall into the broader category of […]

The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 2: Extending the Scope Beyond Olaparib and BRCA1/2 Mutations

Rowan E. Miller, MD, and Jonathan A. Ledermann, MD

  Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical activity in epithelial ovarian cancer, leading both the US Food and Drug Administration (FDA) and the […]

Back to Archive